Elan chief to stick around until Alzheimer's data breaks

Kelly Martin is hanging on to his executive suite at Elan ($ELN) for a few more months. Instead of bowing out May 1 under a longstanding exit plan, Martin has agreed to keep the title and the responsibility for the ultimate outcome of the big Phase III program for the Alzheimer's drug bapineuzumab. Report